Press Releases
Date Title and Summary View
Nov 15, 2013 NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) announced today that management will host a conference call and webcast, to discuss its operational and financial results for the period ended September 30, 2013, on Monday, November 18, 2013 at 4:30pm EST. The Company filed its form 10-Q on November 13, 20...
Nov 14, 2013 NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) today announced that it has appointed Jeffrey Paley, MD to its Board of Directors, effective November 15, 2013. This latest appointment brings the Company's Board to five members. Commenting on today's news, Martin Shkreli, Founder, Presiden...
Nov 4, 2013 Company Obtains Exclusive Option to Acquire Licensable Intellectual Property Resulting from Research NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it will provide funding, over a three-year term, to The Hospital for Sick Children ("SickKids®"), ...
Sep 26, 2013 NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it has elected Cornelius ("Neal") E. Golding to its Board of Directors, effective October 1, 2013. Mr. Golding will also serve as Chairman of the Audit Committee. His appointment brings the Company's Board to four members. ...
Sep 18, 2013 NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) today announced that it has made a proposal to the Board of Directors of Transcept Pharmaceuticals, Inc. (Nasdaq:TSPT) to acquire all of the shares of Transcept common stock that Retrophin does not own for $4.00 per share in cash. Retrophin's propo...
Sep 3, 2013 Corporate Overview Presentation Wednesday, September 11, 2013 at 4:25pm ET NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that Martin Shkreli, Founder, President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare ...
Aug 16, 2013 New York, NY (August 16, 2013), Retrophin, Inc. (OTCQB: RTRX), today announced that it has entered into definitive agreements with a number of new and existing institutional investors in connection with a private placement, or PIPE, financing.  Upon closing of the PIPE financing, Retrophin will receive gross proceeds of approximately $25 ...
Aug 16, 2013 NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it has signed an agreement with a major pharmaceutical company for the exclusive right to negotiate a royalty-bearing U.S. license for a product to be developed for the treatment of Autism and Schizophrenia. Pursuant to the ex...
Aug 16, 2013 Company to Hold Update Conference Call Today, August 16, 2013 at 10:00 a.m. ET NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it has received positive survival results from interim preclinical tests for the Company's compound, RE-024, for the treatmen...
Aug 7, 2013 NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (RTRX), a pharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, today announced that Steven R. Eby, R.Ph has begun serving as a consultant to the Company a...
Page: FirstPrevious ...
13
NextLast
= add release to Briefcase